Transcriptionally targeted gene therapy is a promising experimental modality for treatment of systemic malignancies such as small cell lung cancer (SCLC). We have identified the human achaete-scute homolog 1 (hASH1) and enhancer of zeste homolog 2 (EZH2) genes as highly upregulated in SCLC compared to a panel of representative normal tissues. Here, we evaluate the use of regulatory regions from the hASH1-and EZH2-promoter regions alone and in combination for suicide gene therapy of SCLC. Two hASH1-promoter regions comprising 0.3 and 0.7 kb immediately upstream of (and including) the transcription start site were tested. Both constructs induced reporter gene activity (up to sevenfold SV40-promoter activity) in all tested classic (hASH1 positive) SCLC and in two hASH1-negative SCLC cell lines, whereas gene activity was low or absent (o4% of SV40 activity) in one hASH1-negative SCLC and in all control cell lines tested. To evaluate its therapeutic potential, the 0.7 kb hASH1 proximal-promoter region was evaluated for cytotoxicity in a suicide gene assay. The construct induced SCLC cytotoxicity at levels equivalent to those observed with the SV40 promoter, while control cells remained unaffected by the treatment. Analogously, a 1.1 kb EZH2-promoter region was evaluated by reporter and suicide gene assays. The EZH2 promoter potently induced reporter gene activity in SCLC (up to 25-fold of SV40 activity) while moderate reporter activity (up to 12% of SV40 activity), was detected in the control cells. However, in the suicide gene assay both control and SCLC cells demonstrated sensitivity indicating lack of promoter specificity. Finally, we fused the 0.7 kb hASH1 promoter to the EZH2 promoter generating a chimeric hASH1EZH2 regulatory construct. The chimeric promoter demonstrated increased activity in SCLC cells compared to the hASH1 promoter alone while retaining specificity in control cells. The hASH1EZH2 promoter thus constitutes a promising transcriptional regulator for SCLC gene therapy.
Introduction
Small cell lung cancer (SCLC) accounts for approximately 20% of all diagnosed lung cancers and is characterized by a neuroendocrine phenotype, aggressive progression with fast cell growth and early metastasis. Almost all SCLC patients are diagnosed with disseminated disease requiring systemic treatment and although most patients initially respond well to primary chemotherapy, the far majority experience early relapse resulting in a poor prognosis with a 5-year survival rate lower than 10%. 1 Therefore, there is an urgent demand for novel systemic treatments, which can complement or replace the existing modalities.
Transcriptionally regulated suicide gene therapy constitutes a therapeutic approach with potential for treatment of disseminated malignancies such as SCLC. The strategy is based on the systemic delivery of a cytotoxic gene expressed only in cancer cells resulting in cancer-specific cell death upon suicide gene transcription and prodrug administration. 2 A common suicide gene therapy system is based on the delivery and expression of the herpes simplex virus thymidine kinase (HSVTK) gene, the product of which can convert the nontoxic prodrug ganciclovir (GCV) to a cytotoxic component. 3, 4 Tight regulation of suicide gene expression is critical in order to minimize the exposure of normal tissues to the treatment, and such regulation can be obtained at the level of transcription by introduction of a cancer-specific promoter. However, while retaining cancer specificity, it is important that the promoter induces high gene activity in the target cells in order to induce effective cancer cytotoxicity.
A number of promoters (including regions of the neuron-specific enolase and human telomerase catalytic subunit promoters) have been suggested as regulatory candidates for SCLC gene therapy, [5] [6] [7] [8] but demonstrate incomplete SCLC specificity and/or insufficient activity.
The most intensively studied promoter for cytotoxic gene therapy in SCLC originates from the gastrin-releasing peptide (GRP) gene, which is highly upregulated in SCLC and the GRP promoter demonstrates SCLC cytotoxicity when regulating a suicide gene in vitro and in vivo. 9, 10 On the basis of a global gene expression analysis on a large panel of SCLC cell lines, tumors and normal tissues, we have identified a number of genes with high and specific expression in SCLC compared to normal tissues. 11 Recently, we tested the promoter from one of these genes: insulinoma-associated 1 (INSM1) as a regulator of suicide gene expression. The INSM1 promoter was found to be highly and specifically active in SCLC-cell lines compared to both the highly active (but unspecific) SV40 and the GRP promoters. Furthermore, the INSM1 promoter was capable of inducing high and SCLC-specific cytotoxicity in a suicide gene assay in vitro. 12 Another gene highly upregulated in SCLC encodes the basic helix-loop-helix transcription factor human achaetescute homolog 1 (alias hASH1, ASH1 and ASCL1 in humans and MASH1 in rodents). 13 Global gene expression profiling indicates expression levels of hASH1 to be 5-to 8-fold higher than INSM1 in SCLC suggesting the hASH1 promoter to be a strong regulatory candidate. 11 Importantly, in normal tissues, the hASH1 gene is only transiently activated during certain stages of fetal neuronal development, but is not expressed in normal adult tissues except for low levels in pulmonary neuroendocrine cells and the telencephalic subventricular zone of the brain. [14] [15] [16] The hASH1-promoter region has previously been characterized and the gene was found to be regulated at the promoter level by a general enhancer containing SP1-like binding sites and two specific repressor regions: one proximal and one distal to the transcription start site. 17 The proximal repressor region contains a binding site for the transcription factor hairy and enhancer of split-1 (HES-1), an inhibitor of hASH1 gene transcription in SCLC. 18 Furthermore, the HES-1 upstream activator Notch1 has been found to potently decrease hASH1-mRNA levels in SCLC cells in a HES-1 independent manner and direct transcriptional silencing of the hASH1 gene by exogenous Notch1 expression was recently demonstrated in medullary thyroid cancer (MTC) cells. 19, 20 The gene enhancer of zeste homolog 2 (EZH2) is highly expressed in a number of malignancies including breast cancer and metastatic prostate cancer. [21] [22] [23] and in many proliferating cells and cell lines. EZH2 is a member of the polycomb group of genes and part of a multiprotein complex involved in transcriptional repression of a number of target genes resulting in promoted cell growth. EZH2 gene expression is upregulated by transcription factors of the E2F family due to the presence of E2F responsive elements in the EZH2 promoter, while activated (hypophosphorylated) retinoblastoma (Rb) inhibits EZH2 expression via downregulation of E2F activity. 21 Inactivation of Rb by diverse mechanisms such as gene deletion, mutation or aberrant post-transcriptional regulation has long been considered a hallmark of SCLC. [24] [25] [26] Furthermore, and in concordance with the lack of Rb expression, overexpression of E2F1 and E2F3 has been reported in the majority of SCLC. 27, 28 The EZH2 expression status in SCLC remains to be determined, but the lack of Rb signaling with subsequent upregulation of E2Fs in SCLC suggests that EZH2 gene expression could be upregulated in SCLC cells. Furthermore, microarray data from the global gene expression analysis of SCLC 11 show high expression of EZH2 mRNA in SCLC cell lines, xenografts and tumors (data not shown).
Aiming to develop a new potent and tightly regulated gene therapy strategy for SCLC, we have validated and evaluated hASH1 and EZH2 gene expression in SCLC cell lines and tested promoter regions derived from each gene alone and in combination with regards to their activity and specificity in SCLC and control cells.
We found that both the hASH1 (in accordance with previous studies 11, 13 ) and the EZH2 genes are highly expressed in SCLC. A 0.7 and a 0.3kb hASH1-promoter fragment comprising the hASH1 gene transcription start site showed high and specific activity in SCLC cells. Furthermore, the 0.7 kb construct was fully capable of inducing specific SCLC cell toxicity in a suicide gene assay at levels equivalent to the unspecific SV40 promoter. In contrast, while a 1.1 kb region of the EZH2 promoter also demonstrated high activity and cytotoxicity in SCLC cell lines, weak unspecific activity was observed from this promoter in cell lines of different origin than SCLC. However, when the hASH1 promoter was fused to the EZH2 promoter in a chimeric construct, markedly increased activity was obtained compared to the hASH1 promoter alone in SCLC cells, while SCLC specificity was retained. These results hold promise for the development of a transcriptionally regulated SCLC gene therapeutic strategy based on a hASH1EZH2 chimeric-promoter construct.
Materials and methods

Cell lines
The origin and propagation of the SCLC cell lines DMS53, DMS456, H69, GLC16, DMS273, NCI417 and MARH24 has been previously described in detail. 11 The human non-immortalized fibroblast cell lines CCD19LU and CCD32LU were obtained from American Type Culture Collection, the human glioblastoma cell line U87MG was obtained from Dr W Cavenee (San Diego, CA) and the human non-small cell lung carcinoma (NSCLC) H1299 from Dr RJ Cristiano (Houston, TX). CCD19LU and CCD32LU were propagated in Dulbecco's modified Eagle's medium and H1299 in RPMI all supplemented with 10% fetal calf serum and antibiotics. All cell culture reagents were from Invitrogen (Taastrup, Denmark).
Semiquantitative RT-PCR detection of hASH1-and EZH2 mRNA Total cell RNA was isolated from cell lines using the RNeasy kit (Qiagen, Albertslund, Denmark), and human Cloning of hASH1-promoter constructs Genomic DNA was isolated from the SCLC cell line H69 using the AquaPure Genomic DNA Isolation Kit for cultured cells from Bio-Rad (Herlev, Denmark). Subsequently, the hASH1-promoter fragments were amplified by PCR using the TAKARA LA-Taq DNA polymerase (Cambrex, Vallensbaek, Denmark), with primers containing flanking HindIII-restriction sites (primer sequences see below). For fast insertion of the different hASH1-promoter sequences into the expression vectors, we have developed a cloning system based on the Cre-loxP based Creator protocol (Clontech, BD Biosciences, Brøndby, Denmark). 29 Briefly, the promoter sequence of interest was cloned by PCR with primers containing flanking HindIII-restriction sites and inserted by HindIII digestion and ligation into the multiple cloning site (MCS) of the Creator donor vector pDNR-1r (Clontech). The MCS of pDNR-1r is flanked by two loxP sites allowing for recombination of the promoter sequence into the expression vectors LUC acceptor and HSVTK acceptor containing downstream luciferase and HSVTK genes, respectively. The recombination was performed by mixing of the donor and acceptor vectors and addition of Crerecombinase according to the protocol provided by Clontech.
Expression vector constructs 0.3hASH1-LUC. A 367 bp fragment of the hASH1-promoter spanning from À304 to þ 63 of the ASCL1 gene (sequence derived from GenBank human chromosome 12 accession no. NC_000012, sequence 12q22-q23) was cloned by PCR amplification with primers with flanking HindIII sites (sense: 5 0 -TATTGGCAAGCT TCGCGCCGCCTGTTTATTCAG; antisense: 5 0 -TATT GGCAAGCTTCTTTCACTCGCCCTCCCTGG). After digestion with HindIII, the fragment was inserted into pDNR-1r using the rapid DNA-ligation kit (Roche, Hvidovre, Denmark) and transferred by Cre-recombination into LUC acceptor.
0.7hASH1-LUC.
A 686 bp hASH1-promoter fragment spanning À623 to þ 63 was cloned by PCR with flanking HindIII sites (sense: 5 0 -TATTGGCAAGCTTCCCTCC CCCAACCATGTTTC; antisense as for 0.3hASH1-LUC) and inserted into pDNR-1r followed by Crerecombination into LUC acceptor.
0.7hASH1-HSVTK. The hASH1-promoter fragment from 0.7hASH1-LUC was transferred to HSVTK acceptor by Cre-recombinase-directed recombination.
EZH2-LUC. The EZH2-promoter sequence spanning À1095 to þ 48 cloned into pGL3Basic (Promega, Mannheim, Germany) as previously described 21 was kindly provided by Professor K Helin, Biotech Research and Innovation Center, Copenhagen, Denmark.
EZH2-HSVTK. The EZH2 promoter was amplified from EZH2-LUC DNA by PCR (sense: 5 0 -GGGCTC GAGATCTGCGATCT; antisense: 5 0 -CGGACCGAG CGCCAAACGCG) and inserted into HindIII digested and blunted pDNR-1r followed by Cre-recombination into HSVTK acceptor.
hASH1EZH2-LUC. The hASH1-promoter sequence spanning À623 to À1 (lacking the primary transcription start site) was cloned by PCR with flanking KpnI sites (sense: 5 0 -ATAGGTACCCCCTCCCCCAACCATG TTTC, antisense: 5 0 -GTTGGTACCTGAGAGAGTGCT GGGCTGCC) and ligated into KpnI-digested EZH2-LUC immediately upstream of the EZH2 region.
hASH1EZH2-HSVTK. The hASH1EZH2-promoter sequence was excised from hASH1EZH2-LUC using HindIII and NotI and blunted and inserted into HindIII and NotI digested, blunted modified pGL3Basic where the luciferase gene and polyA tail had been replaced with the HSV-TK gene and polyA tail from pKO Scrambler NTKV-1903 (Stratagene, La Jolla, CA, USA).
The SV40-HSVTK construct was previously described. 12 Transient luciferase reporter gene transfection assay Cells (adherent cells plated 1 day prior to transfection) were transfected in duplicate with 0.5 mg plasmid DNA using Lipofectamine 2000 in OPTIMEM (Invitrogen) in 24-well dishes. For DMS53 and DMS456, 0.2 Â 10 6 cells per well were plated and for all other cell lines 0.1 Â 10 6 cells were plated per well. Suspension cells were added FCS to 10% of total volume and adherent cells were changed to growth medium 3 h after transfection. Cells were lysed 48 h post-transfection in passive lysis buffer, and luciferase activity was measured on a LUMAT LB 9507 Luminometer (Berthold Technologies, Bad Wildbad, Germany) using the Luciferase Assay System (Promega). For each cell line, the luciferase activities of the hASH1-and EZH2-promoter constructs were normalized to the activity from the pGL3-control vector (Promega) containing the luciferase gene regulated by the SV40 promoter and enhancer (SV40-LUC). The hASH1EZH2-LUC activity was compared to that of the 0.7hASH1-promoter fragment cloned into the HindIII site of pGL3Basic to ensure similar plasmid backbones.
Transient HSVTK gene transfection and sensitivity to GCV Cells (2 Â 10 6 ) (adherent cells plated 1 day prior to transfection) were transfected with 3 mg plasmid using Lipofectamine 2000 in OPTIMEM in six-well dishes. After 3 h of transfection, suspension cells were supplemented with 10% FCS and adherent cells were changed to growth medium. At 24 h post-transfection, the cells were plated in duplicate at a density of 2.5 Â 10 4 cells in 100 ml growth medium with different concentrations of GCV (Cymevene, Roche, Hvidovre, Denmark) in 96-well plates. After 5 days (without change of medium), the proliferation was measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma, Brøndby, Denmark) as previously described. 30 For each cell line in each experiment, the data were normalized to transfected cells without addition of GCV.
Generation of cells stably transfected with 0.7hASH1-HSVTK gene and sensitivity to GCV Cells (1 Â 10 6 ) of the SCLC line GLC16 were stably transfected with 8 mg 0.7hASH1-HSVTK. After 24 h, the cells were transferred to medium containing 1 mg ml À1 G418 (Invitrogen) generating a heterogeneous pool of stably transfected cells. Single cell clones were obtained by dilution. To assay the GCV sensitivity of the stably transfected cell population, the cells were plated as described above, incubated with GCV for 7 days and the proliferation response measured by MTT assay was compared to that of the untransfected parental cell line GLC16.
Western blot analyses of Notch1, HES-1 and Rb expression Western blot analyses were performed using a 4-12% Bis-Tris gradient gel (for HES-1) and a 3-8% Tris-acetate gel (for Notch1 and Rb) in the NuPAGE NOVEX PreCast Gel System (Invitrogen). The primary antibodies used were rabbit polyclonal anti-mouse HES-1 kindly provided by Dr T Sudo, Toray Industries Inc. (Japan), and rabbit polyclonal anti-human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (FL-335) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), both diluted 1:10 000. For Notch1 detection, a goat polyclonal antihuman Notch1 (S-20, Santa Cruz) antibody and for detection of phosphorylated and unphosphorylated Rb a mouse monoclonal anti-human retinoblastoma (BD Pharmingen, Franklin Lakes, NJ, USA) antibody both diluted 1:1000 were used.
Coexpression of Notch1 and hASH1-promoterregulated luciferase Cells (3 Â 10 6 cells were replated for secondary transfection with SV40-LUC or 0.7hASH1-LUC, incubated for 48 h followed by quantification of luciferase activity as described above. For statistical evaluation of differences in treatment effects a paired, two-tailed t-test was used.
Results
Endogenous hASH1 and EZH2 expression status in cell lines and normal tissues
The global gene expression profiling of SCLC gene activity showed high expression of hASH1 mRNA in all SCLC tumors and in SCLC cell lines with a classic neuroendocrine phenotype, with low/absent expression in a panel of normal tissues. 11, 32 In order to validate the levels of mRNA expression in selected SCLC cell lines and control cells of non-neuroendocrine origin, semiquantitative RT-PCR was performed. The results confirmed high expression levels of hASH1 transcript in the SCLC cell lines detected as hASH1 positive by the microarray analysis (DMS53, DMS456, H69 and GLC16), whereas hASH1-mRNA expression was low/ absent in hASH1-negative SCLC (DMS273, NCI417, MARH24) and control cell lines (CCD19LU, CCD32LU, H1299, U87MG) ( Figure 1a ).
Microarray analysis of EZH2 gene expression validated by RT-PCR detected low/absent expression in all analyzed adult normal tissues except for testes. In contrast, expression of EZH2 mRNA was detected in all analyzed cell lines regardless of origin (Figure 1b) . 0.3 and 0.7hASH1-promoter activity and cytotoxicity in SCLC and control cells For the current study, two different hASH1-promoter constructs were created: a 0.3 kb hASH1 promoter (0.3hASH1) containing the general enhancer and the proximal repressor and a 0.7 kb construct (0.7hASH1) including the same elements and a putative secondary transcription start site previously identified at À0.5 kb. 17 The two promoter constructs were fused to the luciferase gene generating two hASH1 reporter gene expression vectors termed as 0.3hASH1-LUC and 0.7hASH1-LUC, respectively (Figure 2a) .
Promoter activity was evaluated by measuring luciferase activity after transient transfection of seven SCLC and four non-neuroendocrine control cell lines. To account for variations in transfection efficiency between the cell lines, hASH1-promoter activities were compared to the activity from the unspecific viral SV40 promoter with the SV40 enhancer for each cell line. Very low activity (0-4% of SV40 activity) was observed using both the 0.3 and 0.7hASH1-promoter constructs in the four hASH1-negative control cell lines and in one of the hASH1-negative SCLC cell lines (DMS273). Interestingly, high hASH1-promoter activity was detected in the two SCLC cell lines NCI417 and MARH24 (Figure 2c 
only trace levels of hASH1 mRNA could be detected ( Figure 1a ). All four hASH1-positive SCLC cell lines showed high expression from the two hASH1-promoter constructs proving the functionality of the promoter constructs in hASH1-positive SCLC cells, with activities ranging from 40 to 700% of the SV40-promoter activity (Figure 2b) . A 2.5 kb distal repressor sequence positioned 413 kb upstream of the hASH1 transcription start site has previously been identified. 17 In order to test whether this distal repressor could further increase the promoter specificity, we fused this 2.5 kb distal region to the 0.7hASH1-LUC construct and measured luciferase activity. However, no increase in specificity but a general loss of activity in both SCLC and control cells was detected (data not shown).
While both 0.3hASH1-LUC and 0.7hASH1-LUC induced high and SCLC-specific activity, the results indicated a tendency toward higher activity of 0.7hASH1-LUC in all SCLC cell lines (Figure 2b) . Consequently, this construct was chosen for further studies and the 0.7hASH1-promoter region was fused to the HSVTK gene (0.7hASH1-HSVTK) and evaluated for cytotoxicity after transfection and incubation with GCV. The SCLC cell line H69 and the negative control NSCLC cell line H1299 were transfected with 0.7hASH1-HSVTK, incubated with GCV and cell survival was studied by MTT assay after 5 days. The cytotoxicity was normalized to transfected cells without addition of GCV and compared to that of the unspecific SV40-HSVTK construct.
In H1299, minimal cytotoxicity was observed in cells transfected with 0.7hASH1-HSVTK after exposure to GCV. In contrast, a significant cytotoxic effect was observed with SV40-HSVTK (Figure 2e ). Conversely, in H69 cells transfected with 0.7hASH1-HSVTK, addition of GCV induced cytotoxicity in a pattern similar to that observed using the SV40-HSVTK construct (Figure 2d) .
During transient transfection, only a subset of cells are expected to take up and express the therapeutic gene and the transfection efficiency can vary considerably between the cell lines. Therefore, it was of interest to test whether stable transfectants could induce a full hASH1-promotermediated cytotoxic response to GCV. Thus, the SCLC cell line GLC16 was stably transfected with 0.7hASH1-HSVTK, exposed to GCV and followed by measurement of proliferation. While only a limited sensitivity to GCV could be detected after transient transfection of GLC16 with SV40-and 0.7hASH1-HSVTK (data not shown), the stably transfected cells demonstrated high sensitivity to GCV (Figure 2f ). This was also observed after stable transfection of the SCLC cell line DMS53 (data not shown). In summary, these results demonstrate high and SCLC-specific expression from the 0.7hASH1-promoter construct in SCLC cells. The promoter activity is sufficient to drive expression of a suicide gene and induce specific cytotoxicity and the effect is limited by incomplete transfection efficiency when performed transiently rather than insufficient promoter activity.
Notch1 inhibits hASH1-promoter activity in SCLC cells As mentioned, the two hASH1-negative SCLC cell lines MARH24 and NCI417, showed activity from the hASH1 promoter ranging from 25 to 100% of the level observed with the SV40 promoter. In contrast, another hASH1-negative SCLC cell line DMS273 had only negligible hASH1-promoter activity (Figure 2c ). We speculated that the discrepancy between the endogenous hASH1 expression and hASH1-promoter activity in SCLC could be explained by differences in expression of hASH1-inhibitory transcription factors between these cell lines. HES-1 and Notch1 are known to inhibit hASH1 gene . The graph displays microarray data of the EZH2 gene expression level in human patient tumors obtained as previously described. 11 The insert shows EZH2-mRNA levels in various small cell lung cancer (SCLC) and other cell lines. RT-PCR with actin primers was used as control.
hASH1EZH2 promoter for SCLC gene therapy TT Poulsen et al transcription when introduced into SCLC and MTC cells, 17, 20 and we therefore evaluated the expression of these proteins in the SCLC and control cell lines by western blot analysis (Figure 3a) . HES-1 protein was undetectable in MARH24 or NCI417, while DMS273 expressed high levels. However, HES-1 was also detectable to a variable degree in the four hASH1-positive cell lines, demonstrating that HES-1 expression per se is not sufficient to shut down hASH1-promoter activity in SCLC cells.
Notch1 was detected in all the control cell lines. In SCLC, Notch1 showed markedly high expression in DMS273, whereas the protein levels were low to undetectable in the remaining SCLC cell lines including hASH1EZH2 promoter for SCLC gene therapy TT Poulsen et al NCI417 and MARH24 (Figure 3a) . To test whether Notch1 could inhibit activity from the 0.7hASH1 promoter, cotransfection of either FL-or constitutively active IC-Notch1 expression constructs with 0.7hASH1-LUC was performed in H69 cells, and the luciferase activity was measured after 48 h and compared to that of cells transfected with 0.7hASH1-LUC alone. Since Notch1 was found to inhibit SCLC cell proliferation (data not shown, in accordance with reports from a previous study 33 ), the luciferase data from each 0.7hASH1-LUC/Notch1 transfection were normalized to data from cells transfected with the respective Notch1 construct and SV40-LUC. Both FL-and IC-Notch were found to significantly inhibit 0.7hASH1-promoter-regulated reporter gene activity (Figure 3b) . Thus, the introduction and expression of Notch1 downregulates 0.7hASH1-promoter activity in SCLC cells suggesting lack of Notch1 as an important factor for retaining high hASH1-promoter activity in these cells.
EZH2-promoter activity and cytotoxicity in SCLC and control cells
To evaluate the EZH2-promoter specificity and activity in SCLC and control cells, a 1.1 kb EZH2-promoter region fused to the luciferase reporter gene was transfected as described above. Transfection with EZH2-LUC resulted in up to 25-fold SV40-reporter activity in the evaluated SCLC cell lines, except DMS273 (Figure 4a ), while the reporter gene was more moderately expressed (up to B12% of SV40-promoter activity) in the control cell lines (Figure 4b) .
As previously described, active underphosphorylated Rb inhibits EZH2 expression via downregulation of E2F transcription factors. 21, 34 Furthermore, Rb is very frequently mutated or inactivated in SCLC. [24] [25] [26] We therefore evaluated the Rb expression and phosphorylation status in the SCLC and control cell lines by western blot analysis. Of all the SCLC cell lines, active Rb could only be detected in DMS273, the only SCLC cell line with low EZH2 activity, while the inactive hyperphosphorylated form of Rb was detected in DMS53 and no Rb in the remaining SCLC cell lines (Figure 4c) . Conversely, expression of active hypophosphorylated Rb was detected in the four control cell lines. The results were confirmed by western blot analysis with a primary antibody specific for underphosphorylated Rb (data not shown). The hypothesis that the lack of active Rb in SCLC (possibly in combination with high E2Fs) is responsible for the high activity of the EZH2 promoter region was confirmed by co-transfection of the Rb-negative H69 and GLC16 SCLC cell lines with wild type Rb, resulting in a 50% loss of activity of the EZH2-LUC construct (data not shown).
To test whether the 1.1 kb EZH2 promoter specifically induces cytotoxicity in a suicide gene assay, the promoter was fused to the HSVTK gene and tested in the transient transfection GCV-sensitivity assay previously described. As shown in Figure 4d , the EZH2 promoter induced cytotoxicity of H69 SCLC cells at levels equivalent to SV40. However, the EZH2 promoter also induced potent cytotoxicity in the control cell line H1299 (Figure 4e ). These results demonstrate, that while the EZH2-promoter activity is generally low in control cells and correlates well with the Rb activation status in SCLC, the promoter is sufficiently active to induce cytotoxicity in control cells, thus demonstrating incomplete SCLC specificity.
Fused 0.7hASH1EZH2-promoter activity and cytotoxicity in SCLC and control cells Since the 0.7hASH1-promoter construct demonstrated SCLC-specific activity (Figure 2 ) and the EZH2 promoter demonstrated very potent activity but incomplete specificity (Figure 4) , we tested whether a chimeric-promoter construct comprising of both promoters could increase reporter gene activity compared to the 0.7hASH1 promoter while retaining SCLC specificity. Consequently, the 0.7hASH1 promoter was cloned upstream of the 1.1 kb EZH2 promoter (0.7hASH1EZH2) and the activity was compared to that of the 0.7hASH1 promoter alone. As shown in Figure 5a , the activity of the chimeric construct was potently increased compared to the 0.7hASH1 promoter alone in most SCLC cell lines. In contrast, reporter gene activity remained at low levels (equivalent to hASH1) in all control cell lines except for a less than twofold activity increase in U87MG (equivalent to an increase from 2 to 4% of SV40 activity, data not shown). Furthermore, the 0.7hASH1EZH2 construct fully retained specific SCLC cytotoxicity in the suicide (Figure 5b ), while the transfected control cell line H1299 remained insensitive to GCV treatment (Figure 5c ). Interestingly, when the EZH2 promoter was cloned upstream of the 0.7hASH1 promoter, no significant increase in activity could be detected compared to the hASH1 promoter alone (data not shown).
Discussion
In the current study, we evaluated two hASH1 and one EZH2-promoter constructs alone and in combination for regulation of suicide gene therapy for SCLC. The hASH1 promoters demonstrated specific activity in all the tested hASH1-positive SCLC cell lines, while only trace activity was observed in one hASH1-negative SCLC cell line and in control cell lines of non-neuroendocrine origin, two of which were nonimmortalized lung fibroblasts. In accordance with a previous report, 17 the results indicated higher activity of the 0.7hASH1-promoter construct comprising a secondary transcription start site in all SCLC cell lines (Figures 2b and c) , suggesting an enhancing role of this site in inducing specific gene transcription in SCLC. The 0.7hASH1 construct also induced SCLC-specific cytotoxicity in a HSVTK-GCVbased suicide gene therapy assay (Figures 2d and e) , while introduction of a previously reported 17 distal repressor sequence did not increase the promoter specificity, but resulted in a general loss of activity in both SCLC and control cells in our study (data not shown).
The reporter and suicide gene expression data described above were all obtained by transient transfection. As previously mentioned, in transient transfection studies not all cells will take up and express the plasmid and the transfection efficiency varies between cell lines (resulting in varied sensitivity in suicide gene assays). To determine whether the cytotoxic effect of the 0.7hASH1-HSVTK construct was limited by the transfection efficiency or by insufficient promoter activity, stable transfection was performed with 0.7hASH1-HSVTK in two SCLC cell lines GLC16 and DMS53 with very low sensitivity to GCV after transient transfection. Upon exposure to GCV, the stably transfected cells showed high sensitivity to GCV pointing to limited transfection rather than low promoter activity as the main limiting factor for 0.7hASH1 promoter induced SCLC cell death (Figure 2f and data not shown).
Apart from the activity of the hASH1-promoter regions in hASH1-positive SCLC cells, the constructs also induced reporter gene activation in the two SCLC cell lines NCI417 and MARH24 with very low/undetectable levels of endogenous hASH1 mRNA, while another hASH1-negative SCLC cell line (DMS273) demonstrated low hASH1-promoter activity (Figures 1a and 2c) . Thus, to further elucidate the mechanisms of hASH1-promoter activation in hASH1-positive and -negative SCLC cell lines, we investigated expression of the hASH1 inhibitory transcription factors HES-1 and Notch1 in the cell line panel (Figure 3a) . Notably-and in accordance with results from a previous study 19 -expression of HES-1 was observed in three of four hASH1-positive SCLC cell lines. This demonstrates that expression of HES-1, although previously demonstrated to repress hASH1 activity in SCLC, 18 is not sufficient to knockout hASH1 gene activity in these cells. Furthermore, HES-1 was undetectable in three of the four control cell lines, including the normal lung fibroblasts CCD19LU and CCD32LU, suggesting that other factors than HES-1 account for repression of hASH1-promoter activity in these cells. In contrast, Notch1 was detected in all control cell lines and at very high levels in DMS273, while the hASH1-positive SCLC cell lines, as well as NCI417 and MARH24, expressed low/undetectable levels of Notch1 (Figure 3a) . Finally, cotransfection experiments of the 0.7hASH1-regulated reporter gene in cells pretransfected with Notch1 significantly inhibited hASH1-promoter activity in hASH1-positive H69 SCLC cells (Figure 3b ). In summary, these results point to Notch1 (but not HES-1) as a key inhibitory factor for the hASH1 gene and promoter activity in SCLC.
The three hASH1-negative SCLC cell lines NCI417, MARH24 and DMS273 were originally characterized as 'variant' due to lack of characteristic neuroendocrine features, which are considered hallmarks of SCLC patient tumors. 35, 36 However, during the latest decades, the clinical relevance of the in vitro variant SCLC cell phenotype has been questioned. Although different cell types can be distinguished within a SCLC tumor, no difference has been observed with regards to survival and chemosensitivity between patients with different combined forms of SCLC and the latest WHO classification of lung tumors does not differentiate between different SCLC variants. 37 Indeed, one of the neuroendocrine characteristics of SCLC is high expression of hASH1 and the far majority of SCLC tumors express hASH1 mRNA. 32, 38 Quantitative RT-PCR detection of hASH1-mRNA expression has been even suggested as a sensitive tool to clinically discriminate between SCLC, NSCLC and normal bronchus from limited amounts of biopsy tissue. 39 Therefore, the observation that NCI417 and MARH24 retain hASH1-promoter activity, while lacking expression of endogenous hASH1, may illustrate that the transcriptional regulation of hASH1 expression is partially lost in these cells. The fact that even SCLC cells, which have lost endogenous hASH1-expression retain activity from the 0.7hASH1-promoter fragment may be of advantage for targeting heterogeneous SCLC tumors, although this remains to be fully elucidated. The 1.1 kb EZH2-promoter region was found to induce very high reporter activity in all SCLC cell lines except DMS273, while moderate activity was detected in the control cell lines. EZH2 gene activity has been reported to be upregulated by E2F transcription factors, and putative E2F-binding sites have been identified in the EZH2 promoter. 34 Since Rb in its active hypophosphorylated state binds to and downregulates E2F (and hence EZH2) activity, 21 we investigated Rb expression and activation status by western blot analysis. All the SCLC cell lines with high EZH2 activity either completely failed to demonstrate Rb expression or only inactive hyperphosphorylated Rb could be detected. In contrast, the active underphosphorylated form of Rb was detected in DMS273, the only SCLC cell line to demonstrate low activity from the EZH2 promoter as well as in the control cell lines (Figure 4c ). These data suggest that the lack of functional Rb in SCLC cells allows for upregulation of E2F activity, resulting in increased EZH2 activity. While the endogenous EZH2 gene expression was generally low or absent in the normal tissues investigated by microarray and semiquantitative RT-PCR analysis, all the control cell lines were found to express the gene (Figure 1b) . The uniform expression of the EZH2 gene in cell lines is not surprising, since many studies have found EZH2 to stimulate cell proliferation and cell-cycle progression. 21, 22, 40, 41 This may also explain the EZH2 transcript observed in testes, a highly proliferating tissue. However, EZH2 expression in proliferating cells and tissues raises concern with regards to the specificity of an EZH2-promoter-regulated suicide gene construct. Indeed, in the HSVTK-based cytotoxicity assay, both the tested SCLC and control cell lines demonstrated high sensitivity to GCV upon EZH2-HSVTK transfection, suggesting incomplete SCLC specificity (Figures 4d and e) .
Since the 0.7hASH1 promoter provided SCLC-specific activity and the EZH2 promoter induced very high reporter activity, but incomplete specificity, we asked whether fusion of the 0.7hASH1 and EZH2 promoters in hASH1EZH2 promoter for SCLC gene therapy TT Poulsen et al a chimeric construct could further increase reporter activity compared to the 0.7hASH1 promoter alone in a SCLC-specific manner. Indeed, we found that the chimeric construct increased reporter activity while retaining specificity in SCLC cells ( Figure 5 ). These results suggest that the regulatory factors involved in the downregulation of 0.7hASH1-promoter activity in the control cells retain functionality in the chimeric construct.
Recently, a 0.3 kb core promoter region from the murine hASH1-gene ortholog MASH1 was evaluated as a specific transcriptional regulator in the neuroendocrine child malignancy neuroblastoma. The promoter demonstrated high activity and specificity in both a reporter and a suicide gene assay in neuroblastoma cells in vitro. 42 The activity of the MASH1-promoter construct was compared to the highly active CMV promoter, reporting a MASH1-promoter activity equivalent to 1-6% of the CMVpromoter activity in non-neuroblastoma control cell lines. We have found the CMV promoter to be up to 10-fold more active than the SV40 promoter (unpublished observation), suggesting that activity of the 0.3 kb MASH1-construct might not be completely restricted to neuroendocrine cells. For comparison, the activity of the 0.7hASH1 and 0.7hASH1EZH2-promoter constructs in our study were as low as 0-4% of the SV40-promoter activity in the four control cell lines tested in our study (Figures 2 and 5) .
A number of studies demonstrated that members of the myc-family activate MASH1 transcription. Gene amplification and/or overexpression of the myc gene family (c-myc, N-myc and L-myc) is a hallmark of SCLC 43 and the overexpression of L-myc and N-myc has previously been shown to be involved in activation of hASH1 in SCLC and neuroblastoma cells. 44 The SCLC cell lines used in this study all abundantly express either L-myc, Nmyc or C-myc 45 (data not shown), and binding of N-myc to the core MASH1 promoter has recently been demonstrated in neuroblastoma cells, 46 suggesting a direct role of the myc family proteins in promoter activation in mice. In the same study, a screening of MASH1 gene flanking sequences was performed identifying a 0.2 kb enhancer sequence far distal to the MASH1 start site, which induces a 3-to 4-fold increase in activity of the core 0.3 kb MASH1 promoter in neuroblastoma cells. Furthermore, the authors found a significant increase in activity of the MASH1 promoter with the enhancer sequence in the SCLC cell line NCI417 compared to the core promoter alone, although the increase was lower than that observed in neuroblastoma cell lines. 46 The isolated MASH1 enhancer shows high homology with a corresponding area upstream of the rat MASH1 gene (positioned on chromosome 7), but there was poor homology with the hASH1-flanking regions on human chromosome 12. These results suggest that ASH1 expression may be regulated differentially between species, although this remains to be further elucidated. Adding to the complexity, it is worth mentioning that a murine embryonic central nervous system-specific enhancer has been identified, but this region failed to increase the activity of the 0.3 kb core MASH1 promoter in neuroblastoma cells, 46, 47 demonstrating that the mechanisms involved in regulating MASH1 gene activity can vary between embryonic and different malignant tissues.
In summary, this study is the first to evaluate the use of the hASH1 and EZH2 promoters alone and in combination for targeted suicide gene therapy of SCLC. We find high and SCLC-specific activity of a hASH1EZH2 chimeric-promoter construct exclusively in SCLC cells, while only trace expression was detected in four control cell lines of different non-neuroendocrine origin. Furthermore, the hASH1EZH2-promoter construct demonstrates SCLC-specific cytotoxicity in a suicide gene assay. As such, the results hold promise for use of the hASH1EZH2 chimeric promoter for systemically applied gene therapy for SCLC.
